Final recommendation from NICE on Simponi for ankylosing spondylitis
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has issued final guidance recommending Merck & Co's subcutaneous anti-TNF-alpha monoclonal antibody Simponi (golimumab) as a treatment option for ankylosing spondylitis. But as described in earlier draft guidance, there are certain conditions attached to the recommendation (scripintelligence.com, 24 June 2011).